Compare Stocks: KYTX, SRPT, TSHA, and LKFT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYTX Kyverna Therapeutics	$8.95 +9.5%	$8.10	$3.27 ▼ $13.67	$505.26M	1.93	765,786 shs	1.14 million shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$27.52 0.0%	$28.67	$25.68 ▼ $37.78	$1.81B	0.27	226,151 shs	425,485 shs
SRPT Sarepta Therapeutics	$18.18 +0.4%	$17.13	$14.68 ▼ $25.32	$1.91B	0.24	3.00 million shs	1.73 million shs
TSHA Taysha Gene Therapies	$6.21 +4.4%	$6.12	$2.71 ▼ $7.30	$1.94B	1.22	2.51 million shs	3.05 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYTX Kyverna Therapeutics	+9.55%	+13.43%	+20.13%	+2.87%	+154.99%
LKFT Lakefront Biotherapeutics American Depositary Shares	-0.04%	+2.27%	-8.30%	+3.42%	-15.24%
SRPT Sarepta Therapeutics	+0.44%	+5.82%	+5.57%	+9.25%	-16.64%
TSHA Taysha Gene Therapies	+4.37%	-2.51%	+4.19%	+19.88%	+111.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYTX Kyverna Therapeutics	$8.95 +9.5%	$8.10	$3.27 ▼ $13.67	$505.26M	1.93	765,786 shs	1.14 million shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$27.52 0.0%	$28.67	$25.68 ▼ $37.78	$1.81B	0.27	226,151 shs	425,485 shs
SRPT Sarepta Therapeutics	$18.18 +0.4%	$17.13	$14.68 ▼ $25.32	$1.91B	0.24	3.00 million shs	1.73 million shs
TSHA Taysha Gene Therapies	$6.21 +4.4%	$6.12	$2.71 ▼ $7.30	$1.94B	1.22	2.51 million shs	3.05 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYTX Kyverna Therapeutics	+9.55%	+13.43%	+20.13%	+2.87%	+154.99%
LKFT Lakefront Biotherapeutics American Depositary Shares	-0.04%	+2.27%	-8.30%	+3.42%	-15.24%
SRPT Sarepta Therapeutics	+0.44%	+5.82%	+5.57%	+9.25%	-16.64%
TSHA Taysha Gene Therapies	+4.37%	-2.51%	+4.19%	+19.88%	+111.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KYTX Kyverna Therapeutics	2.67	Moderate Buy	$30.00	235.20% Upside
LKFT Lakefront Biotherapeutics American Depositary Shares	2.25	Hold	$30.67	11.43% Upside
SRPT Sarepta Therapeutics	2.20	Hold	$25.06	37.84% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	105.62% Upside

Current Analyst Ratings Breakdown

Latest KYTX, SRPT, TSHA, and LKFT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	SRPT Sarepta Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$30.00 ➝ $26.00
8/11/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Sector Perform	$28.00 ➝ $26.00
8/5/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/4/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
7/28/2026	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/21/2026	TSHA Taysha Gene Therapies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $13.00
7/20/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/10/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Equal Weight	$30.00
7/9/2026	SRPT Sarepta Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$23.00 ➝ $20.00
7/9/2026	SRPT Sarepta Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$27.00

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$3.85 per share	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	$990.57M	1.83	$0.73 per share	37.92	$47.57 per share	0.58
SRPT Sarepta Therapeutics	$2.20B	0.87	N/A	N/A	$10.89 per share	1.67
TSHA Taysha Gene Therapies	$5.49M	368.90	N/A	N/A	$0.90 per share	6.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KYTX Kyverna Therapeutics	-$161.31M	-$2.94	N/A	N/A	N/A	N/A	-81.92%	-63.74%	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	$363.05M	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	-$713.41M	-$2.90	N/A	9.88	0.24	-13.48%	-1.60%	-0.66%	11/4/2026 (Estimated)
TSHA Taysha Gene Therapies	-$109M	-$0.42	N/A	N/A	N/A	N/A	-56.19%	-41.84%	11/3/2026 (Estimated)

Latest KYTX, SRPT, TSHA, and LKFT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KYTX Kyverna Therapeutics	-$0.6783	-$0.63	+$0.0483	-$0.63	N/A	N/A
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
8/10/2026	Q2 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$0.9672	$0.04	+$1.0072	$0.04	$7.29 million	$15.47 million
8/5/2026	Q2 2026	SRPT Sarepta Therapeutics	$0.2173	$0.64	+$0.4227	-$0.05	$366.39 million	$401.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KYTX Kyverna Therapeutics	0.15	9.06	9.06
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	32.84	32.72
SRPT Sarepta Therapeutics	0.55	4.42	2.62
TSHA Taysha Gene Therapies	0.13	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KYTX Kyverna Therapeutics	18.08%
LKFT Lakefront Biotherapeutics American Depositary Shares	32.46%
SRPT Sarepta Therapeutics	86.68%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
KYTX Kyverna Therapeutics	17.60%
LKFT Lakefront Biotherapeutics American Depositary Shares	2.91%
SRPT Sarepta Therapeutics	6.90%
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KYTX Kyverna Therapeutics	96	61.84 million	50.96 million	Optionable
LKFT Lakefront Biotherapeutics American Depositary Shares	1,310	65.90 million	63.98 million	Optionable
SRPT Sarepta Therapeutics	1,372	105.63 million	98.34 million	Optionable
TSHA Taysha Gene Therapies	180	325.83 million	314.50 million	Optionable

KYTX, SRPT, TSHA, and LKFT Headlines

Recent News About These Companies

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages

4 hours ago | marketbeat.com

Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)

August 14, 2026 | theglobeandmail.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down on Disappointing Earnings

August 14, 2026 | americanbankingnews.com

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

August 13, 2026 | finance.yahoo.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6% - Here's Why

August 13, 2026 | marketbeat.com

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | finanznachrichten.de

Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...

August 12, 2026 | finance.yahoo.com

Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026

August 12, 2026 | seekingalpha.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings

August 12, 2026 | marketbeat.com

Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA

August 12, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Taysha Gene Therapies Q2 Earnings Call Highlights

August 11, 2026 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

August 11, 2026 | marketbeat.com

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | globenewswire.com

Taysha Gene Therapies (TSHA) Expected to Post Quarterly Earnings on Tuesday

August 10, 2026 | americanbankingnews.com

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

August 4, 2026 | globenewswire.com

Taysha Gene Therapies (TSHA) to Announce Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Taysha Taps Catalent for Potential Commercial Manufacturing of TSHA-102

August 3, 2026 | finance.yahoo.com

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

August 3, 2026 | globenewswire.com

Seven Fleet Capital Management LP Has $2.80 Million Holdings in Taysha Gene Therapies, Inc. $TSHA

August 2, 2026 | marketbeat.com

ADAR1 Capital Management LLC Has $13.32 Million Stock Position in Taysha Gene Therapies, Inc. $TSHA

July 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX, SRPT, TSHA, and LKFT Company Descriptions

Kyverna Therapeutics NASDAQ:KYTX

$8.95 +0.78 (+9.55%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$8.72 -0.23 (-2.61%)

As of 08:57 AM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

$27.52 -0.01 (-0.04%)

As of 08/17/2026 04:00 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Sarepta Therapeutics NASDAQ:SRPT

$18.18 +0.08 (+0.44%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$18.14 -0.04 (-0.19%)

As of 09:01 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Taysha Gene Therapies NASDAQ:TSHA

$6.21 +0.26 (+4.37%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$6.22 +0.01 (+0.24%)

As of 07:50 AM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYTX, SRPT, TSHA, and LKFT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYTX, SRPT, TSHA, and LKFT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYTX, SRPT, TSHA, and LKFT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX, SRPT, TSHA, and LKFT Company Descriptions

Kyverna Therapeutics NASDAQ:KYTX

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Sarepta Therapeutics NASDAQ:SRPT

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYTX, SRPT, TSHA, and LKFT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYTX, SRPT, TSHA, and LKFT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYTX, SRPT, TSHA, and LKFT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX, SRPT, TSHA, and LKFT Company Descriptions

Kyverna Therapeutics NASDAQ:KYTX

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Sarepta Therapeutics NASDAQ:SRPT

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools